Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
Joshua W Fleming, Laurie W Fleming, Courtney S Davis Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, MS, USA Abstract: Canagliflozin–metformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/51b6f1065edd49b49bb7dc6dcc1ee034 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:51b6f1065edd49b49bb7dc6dcc1ee034 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:51b6f1065edd49b49bb7dc6dcc1ee0342021-12-02T07:42:12ZFixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination1178-7007https://doaj.org/article/51b6f1065edd49b49bb7dc6dcc1ee0342015-06-01T00:00:00Zhttp://www.dovepress.com/fixed-dose-combinations-in-type-2-diabetes-ndash-role-of-the-canaglifl-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Joshua W Fleming, Laurie W Fleming, Courtney S Davis Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, MS, USA Abstract: Canagliflozin–metformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2DM). Canagliflozin is an inhibitor of the sodium–glucose co-transporter 2 which causes an increase in the urinary excretion of glucose. In the present article, we review the safety and efficacy of canagliflozin and metformin from data obtained from Phase III metformin add-on therapy clinical trials as there are no studies to date that specifically evaluate the combination of metformin and canagliflozin. Trials included in this review were dual-therapy trials of subjects who were already taking background metformin and were assigned to receive canagliflozin, glimepiride, or sitagliptin. The addition of canagliflozin to metformin resulted in a decrease in HbA1c of 0.73%–0.93%. Canagliflozin 100 mg was considered to be non-inferior to glimepiride and sitagliptin 100 mg with the canagliflozin 300 mg dose being statistically superior to sitagliptin and glimepiride. Other advantages of the use of canagliflozin are reduction in weight (3.3–4.0 kg) and systolic blood pressure (3.3–4.7 mmHg). The primary disadvantages are potential genital mycotic infections, hypotension, and gastrointestinal side effects from metformin. All things considered, this combination appears to be safe and effective in clinical trials and represents a promising option for the treatment of T2DM. Keywords: type 2 diabetes, fixed-dose combination (FDC), canagliflozin metformin Fleming JWFleming LWDavis CSDove Medical PressarticleSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2015, Iss default, Pp 287-294 (2015) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Specialties of internal medicine RC581-951 |
| spellingShingle |
Specialties of internal medicine RC581-951 Fleming JW Fleming LW Davis CS Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination |
| description |
Joshua W Fleming, Laurie W Fleming, Courtney S Davis Department of Pharmacy Practice, The University of Mississippi School of Pharmacy, Jackson, MS, USA Abstract: Canagliflozin–metformin is one of the newest combination therapies available for the treatment of type 2 diabetes mellitus (T2DM). Canagliflozin is an inhibitor of the sodium–glucose co-transporter 2 which causes an increase in the urinary excretion of glucose. In the present article, we review the safety and efficacy of canagliflozin and metformin from data obtained from Phase III metformin add-on therapy clinical trials as there are no studies to date that specifically evaluate the combination of metformin and canagliflozin. Trials included in this review were dual-therapy trials of subjects who were already taking background metformin and were assigned to receive canagliflozin, glimepiride, or sitagliptin. The addition of canagliflozin to metformin resulted in a decrease in HbA1c of 0.73%–0.93%. Canagliflozin 100 mg was considered to be non-inferior to glimepiride and sitagliptin 100 mg with the canagliflozin 300 mg dose being statistically superior to sitagliptin and glimepiride. Other advantages of the use of canagliflozin are reduction in weight (3.3–4.0 kg) and systolic blood pressure (3.3–4.7 mmHg). The primary disadvantages are potential genital mycotic infections, hypotension, and gastrointestinal side effects from metformin. All things considered, this combination appears to be safe and effective in clinical trials and represents a promising option for the treatment of T2DM. Keywords: type 2 diabetes, fixed-dose combination (FDC), canagliflozin metformin |
| format |
article |
| author |
Fleming JW Fleming LW Davis CS |
| author_facet |
Fleming JW Fleming LW Davis CS |
| author_sort |
Fleming JW |
| title |
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination |
| title_short |
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination |
| title_full |
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination |
| title_fullStr |
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination |
| title_full_unstemmed |
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination |
| title_sort |
fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination |
| publisher |
Dove Medical Press |
| publishDate |
2015 |
| url |
https://doaj.org/article/51b6f1065edd49b49bb7dc6dcc1ee034 |
| work_keys_str_mv |
AT flemingjw fixeddosecombinationsintype2diabetesndashroleofthecanagliflozinmetformincombination AT fleminglw fixeddosecombinationsintype2diabetesndashroleofthecanagliflozinmetformincombination AT daviscs fixeddosecombinationsintype2diabetesndashroleofthecanagliflozinmetformincombination |
| _version_ |
1718399223716642816 |